🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Eagle Pharmaceuticals to Delist from Nasdaq

EditorAhmed Abdulazez Abdulkadir
Published 17/11/2024, 09:02 am
EGRX
-

Eagle Pharmaceuticals, Inc. (NASDAQ:OTC:EGRX) has announced its intention to voluntarily delist its common stock from the Nasdaq Global Market. This move follows the company's suspension from Nasdaq on October 3, 2024, due to non-compliance with listing rules.

The pharmaceutical company, headquartered in Woodcliff Lake, New Jersey, initially received a delisting notice from Nasdaq on October 1, 2024, after failing to meet the Nasdaq Listing Rule 5250(c)(1). Since October 4, 2024, Eagle Pharmaceuticals' stock has been trading on the OTC Expert Market under the symbol "EGRX."

Eagle Pharmaceuticals plans to file a Form 25 with the U.S. Securities and Exchange Commission (SEC) on or after November 25, 2024, to finalize the delisting process. This filing is expected to become effective no earlier than ten days after submission. The delisting from Nasdaq will also lead to the deregistration of the common stock under Section 12(b) of the Securities Exchange Act of 1934, which is anticipated to reduce some of the company's reporting obligations to the SEC.

The company's decision is part of the previously disclosed process to address its inability to regain compliance with Nasdaq's continued listing standards. The transition to the OTC Expert Market is a result of the suspension from Nasdaq and is intended to provide a trading platform for the company's stock moving forward.

InvestingPro Insights

Eagle Pharmaceuticals' decision to voluntarily delist from Nasdaq comes amid significant financial challenges, as reflected in recent InvestingPro data. The company's stock has experienced a dramatic decline, with a 92.07% drop in the past year and an 86.61% decrease year-to-date. This downward trend is further emphasized by the stock's current price being only 7.14% of its 52-week high.

InvestingPro Tips highlight the stock's high price volatility and significant price drops over various time frames, aligning with the company's current delisting situation. The stock's recent performance, including a 17.69% decline in the past week, underscores the ongoing challenges Eagle Pharmaceuticals faces.

Despite these setbacks, it's worth noting that the stock has shown a 16.75% return over the last month, possibly indicating some short-term investor interest or market reactions to the company's strategic decisions.

For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights that could provide valuable context to Eagle Pharmaceuticals' current situation and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.